TCRT — Stock Film
STOCK FILMSCENE 1/11TCRT · $1.80
Stock Expert AI presents
TCRT
Alaunos Therapeutics, Inc
~4 min film100% real numbers0 jargon
WHAT DOES THIS COMPANY DO?
Alaunos Therapeutics, Inc. A quick introduction.

On the stock market since 2005, it operates in the world of health and science. It has 1 employee. Now — the numbers.

on the stock market since 2005
1 employee
$4.7M market value
Revenue last year:
$0
The loss that same year:
$0
For every $1 it earns, the company spends $836.

The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.

THE SALES TREND
Sales have been shrinking.

An average decline of 67% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.

$398K
2021
$2.9M
2022
$5K
2023
$10K
2024
$5K
2025
In the vault right now:
$0
DEBT: $0
At this pace, that money lasts less than a year.

Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.

INSIDE THE REPORT CARD

We compared this company with its own sector across five subjects.

A score of 50 means class average.

BUSINESS QUALITY
4
very weak

Clearly below the class average.

FINANCIAL STRENGTH
38
weak

Clearly below the class average.

VALUATION
3
very weak

Clearly below the class average.

GROWTH
27
very weak

Clearly below the class average.

PRICE MOMENTUM
23
very weak

Clearly below the class average.

WORTH WATCHING

Valuation: The stock trades at a price that looks expensive next to its earnings; that can cap future returns.

Business Quality: Profit power and business quality trail similar companies in the sector.

THE COUNCIL REVIEW
9

angles, checked one by one.

The 5 that stand out are on screen; the rest came back neutral.

The council scores out of 10; report-card grades are out of 100.

STRENGTHS
Heavy investment in the future10/10
Few are betting against it10/10
WEAK SPOTS
The stock has lost its spark0/10
Growth has stalled2/10
Each sale is made at a loss3/10
WORTH WATCHING

Revenue Growth: Sales are growing slowly.

THE FIVE-YEAR JOURNEY
A big climb, then a hard fall.

An investor who bought at the very peak is down 100% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.

1
THE BRIGHT SIDE · 1/2
Delivers on expectations

It met or beat analyst expectations in 7 of the last 7 quarters — consistency is a promise kept.

2
THE BRIGHT SIDE · 2/2
Executives are buying their own stock

Over the last 12 months, company executives reported 22 buys and 0 sells. Management buying with its own money is usually read as a good sign.

1
THE RISKS · 1/2
Small sales, big loss

A loss of $4.2M against $5K in annual sales. And on top of that, sales fell from the year before.

2
THE RISKS · 2/2
The cash has a countdown

At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.

FINALE · THE GRADE
F
0 / 100 · MoonshotScore

On our five-subject report card, TCRT sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”

The takeaway: TCRT is a small company that closed last year at a loss. The road back to profit runs through spending discipline.

What would you like to do next?
Open the stock page →
This was a film — not investment advice.
Data: FMP & company filings
Aug 21, 2026 · stockexpertai.com · Stock Film